On the upcoming ACAM-529 vaccine trial

something differentDavid Knipe, Lynda Morrison, and Jeffrey Cohen are three of the principal scientists who have been involved in research over the past 15 years that has brought the HSV-2 ACAM-529 vaccine to a Phase I Clinical Trial.  Sanofi Pasteur is the company that has backed / sponsored the ACAM-529 vaccine, and Sanofi Pasteur will presumably be bringing the HSV-2 ACAM-529 vaccine to market if it succeeds in all phases of human clinical trials.

Dr. Knipe was kind enough to share the following information with me earlier today, which I pass along for those who may be interested in enrolling in the ACAM-529 vaccine clinical trial.

————————————————————–

Hi Bill,

Here are the links for the start of the HSV5-29 trial for your blog.

http://www.niaid.nih.gov/news/newsreleases/2013/Pages/HSV11-8-13.aspx

http://hms.harvard.edu/news/targeting-hsv-11-8-13

If people want to write to me about the trial (I am not conducting it though), they can write to me at this address:  dknipe@hms.harvard.edu

Best,
David

—————————————————————

David, I believe that I speak for millions of genital herpes sufferers worldwide when I say thank you for your dedication and perseverance over the past 15 years, which has brought ACAM-529 from a HSV-2 vaccine concept to the first human clinical trial of a HSV-2 viral vaccine that has real potential to be a game-changer.

You have my best wishes and hopes that the trials of the HSV-2 ACAM-529 vaccine represent a turning point in the development of a HSV-2 genital herpes vaccine that is both safe and effective.

– Bill H.